Orgenesis Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: ORGS · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1460602
| Field | Detail |
|---|---|
| Company | Orgenesis INC. (ORGS) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $750,000, $250,000, $1,000,000, $15 m, $1.03 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: OGN
TL;DR
OGN filed an 8-K for a material agreement and equity sales - watch for details.
AI Summary
On August 21, 2024, Orgenesis Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and financial obligations are not fully disclosed in this initial filing.
Why It Matters
This filing indicates significant corporate activity, including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and financial obligations, which inherently carry financial risk, and unregistered equity sales can dilute existing shareholders.
Key Players & Entities
- Orgenesis Inc. (company) — Registrant
- August 21, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Orgenesis Inc. on August 21, 2024?
The filing states that Orgenesis Inc. entered into a material definitive agreement on August 21, 2024, but the specific details of this agreement are not provided in the initial report.
What type of financial obligation was created by Orgenesis Inc.?
Orgenesis Inc. created a direct financial obligation or an obligation under an off-balance sheet arrangement, as reported in the filing.
What information is provided regarding unregistered sales of equity securities?
The filing indicates that there were unregistered sales of equity securities by Orgenesis Inc., but the specifics of these sales, such as the amount or price, are not detailed in this report.
What is the state of incorporation for Orgenesis Inc.?
Orgenesis Inc. is incorporated in Nevada.
What is the primary business of Orgenesis Inc. according to its SIC code?
Orgenesis Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 971 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-08-26 16:05:13
Key Financial Figures
- $750,000 — enesis Maryland an additional amount of $750,000 and amend the terms of the parties' ori
- $250,000 — ne 26, 2024, in the principal amount of $250,000, for a total principal amount of $1,000
- $1,000,000 — 50,000, for a total principal amount of $1,000,000 under the Note (the "Loan Amount"). The
- $15 m — an aggregate gross proceeds of at least $15 million, the Note holder may require repa
- $1.03 — of the Company at an exercise price of $1.03 per share. If Orgenesis Maryland fails
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex4-1.htm (EX-4.1) — 83KB
- ex10-1.htm (EX-10.1) — 42KB
- 0001493152-24-033866.txt ( ) — 361KB
- orgs-20240821.xsd (EX-101.SCH) — 3KB
- orgs-20240821_lab.xml (EX-101.LAB) — 33KB
- orgs-20240821_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORGENESIS INC. Date: August 26, 2024 By: /s/ Victor Miller Victor Miller Chief Financial Officer, Treasurer and Secretary